Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]

  • Awaiting development
  • GID-TA11753
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Elranatamab within its marketing authorisation for treating relapsed or refractory multiple myeloma